Gerber Products Company logo, baby food and baby product brand, graphic element on white via Associated Press
Contamination concerns have forced Gerber to pull some of its baby formula from store shelves.
Gerber parent company Perrigo issued a voluntary recall of Gerber's Good Start SoothePro Infant Formula "out of an abundance of caution" regarding a link to possible Cronobacter sakazakii contamination.
The impacted products were manufactured in Eau Claire, Wisconsin between January 2 and January 18.
"Importantly, no distributed product has tested positive for the presence of this bacteria, no adverse events have been reported and no other products manufactured at this facility or any other of Perrigo's facilities are affected by this recall," the company said in a statement.
Cronobacter sakazakii is a bacteria that is relatively common and typically does not impact most people, but when newborns and infants with compromised immune systems are exposed, it can potentially cause sepsis and meningitis, according to the Centers for Disease Control and Prevention.
"Every batch of infant formula is tested to make certain it meets stringent nutritional, safety, quality and regulatory requirements," Perrigo Company stated.
The recall comes just a month after an Enfamil baby formula recall due to concerns over the same kind of contamination.
The health and wellness industry is booming, expected to hit $14 trillion by 2032. Equinox teamed up with Function Health to revolutionize health optimization.
Featherie, a line of sustainable and functional golf wear for girls, fills a void in the market, catering to the increasing number of female junior golfers.
The CEO of LiveOne, Rob Ellin, discusses the DOJ's lawsuit against Live Nation and Ticketmaster, how will if affect you and the future of live events. Watch!
Nvidia did a record $26 billion in sales in the latest quarter. And get ready for the stock to keep climbing, because the A.I. boom is just getting started.
In honor of National Cancer Research Month, Perspective Therapeutics discusses its latest treatment — currently in clinical trials — that targets cancer cells d